Placentia, California — August 5, 2025 — Leads & Copy — InVitro International (OTCQB: IVRO) announced FY ’25, Q3 sales of $234,430, a 39.7% increase over the same period in FY ’24. Year-to-date sales of $675,080 are up 14.4% from FY ’24, with net income for the first three quarters of FY ’25 reaching $95,556, a 17.1% increase over the same period last year.
CEO and Chairman W. Richard Ulmer expressed satisfaction with IVRO’s progress, noting increased inquiries from chemical companies recognizing the cost and time inefficiencies of animal testing, especially as regulations evolve. Canada recently prohibited new cosmetics that rely on animal testing, and several U.S. agencies will now accept validated in vitro test results, which IVRO offers. The company anticipates similar legislation in the U.S.
InVitro International, Inc., founded in 1985, provides non-animal testing methods, producing regulatory-approved data on corrosivity and ocular/dermal irritation. Their technology is available globally through test kits and partner laboratory services.
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
Source: InVitro International, Inc.
